User:C Michael Gibson

Revision as of 22:54, 29 January 2009 by C Michael Gibson (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
WikiDoc Founder C. Michael Gibson, M.S., M.D.

C. Michael Gibson M.S., M.D., Associate Professor of Medicine, Harvard Medical School

Founder WikiDoc and WikiPatient, Chairman of the Board, WikiDoc Foundation (a 509 (a)(1) Charitable Organization)

Contact: mailto:mgibson@wikidoc.org; Phone 617-525-6884

Address: C. Michael Gibson, M.S., M.D., 350 Longwood Avenue, First Floor, Boston MA, 02115.


Dr. Gibson received his B.S., M.S., and M.D. degrees from the University of Chicago. He was an Intern, Resident and Chief Resident at the Brigham and Women’s Hospital, Harvard Medical School. He received his training as an interventional cardiologist and served as the Director of the Coronary Care Unit at Beth Israel Hospital, Harvard Medical School. Dr. Gibson then served as the Chief of Cardiology and Director of Interventional Cardiology at the West Roxbury Veterans Affairs Medical Center, Harvard Medical School. While at the West Roxbury VA, he also served as an Associate Physician at the Brigham and Women’s Hospital. He then moved on to Allegheny General Hospital as Vice Chairman of Medicine for Clinical Research and Director of Invasive Cardiology. He subsequently relocated to the west coast and served as Associate Chief of Cardiology, Chief of Interventional Cardiology and Director of the Cardiac Catheterization Laboratory at University of California San Francisco (UCSF). Dr. Gibson has now returned to Harvard Medical School in Boston. Until 2003, Dr. Gibson served as Chief Academic Officer and Director of Core Services at Harvard Clinical Research Institute (HCRI), until 2005 he served as Associate Chief of Cardiology and Director of Academic Affairs in the Cardiovascular Division at the Beth Israel Deaconess Medical Center. Until 2009 he served as the Director of the TIMI Data Coordinating Center at the Brigham and Women’s Hospital. He is currently a full time interventional cardiologist and Chief of Clinical Research in the Cardiovascular Division at Beth Israel Deaconess Medical Center, Harvard Mediccal School.

Dr. Gibson’s work has largely focused on the development of the statistical and angiographic methods to investigate the pathophysiology of coronary artery disease and the efficacy of therapeutic modalities. He has directed the angiographic core laboratory for a wide variety of studies including acute MI studies, unstable angina studies, interventional trials, peripheral interventional trials, angiogenesis trials (VEGF), imaging modality studies, managed care analyses for HCFA, and atherosclerosis regression trials such as the NIH-sponsored Harvard Atherosclerosis Reversibility Project (HARP). His work has been presented in over 1000 manuscripts, abstracts, trial summaries, textbooks and textbook chapters.


Within the Thrombolysis In Myocardial Infarction (TIMI) Study Group, Dr. Gibson is a Principle Investigator of multiple international acute MI trials within the TIMI Study Chairman’s Office. Dr. Gibson served as the Director of the TIMI data Coordinating and led the creation of the master database that unified data from over 25 years of TIMI studies (TIMI 1-50) in nearly 100,000 patients. Dr. Gibson also served as the Director of the TIMI Angiographic Core Laboratory. Gibson invented the TIMI frame count (CTFC) in which the number of cineframes for dye to reach standardized distal landmarks is counted (an index of epicardial blood flow). On google scholar, the TIMI Frame Count is listed as being cited in about 3,700 articles (for updated numbers click here) Dr. Gibson also invented the TIMI myocardial perfusion grade (a measure of microvascular perfusion. The TIMI frame count and the TIMI myocardial perfusion grade are both multivariate predictors of 2 year mortality in acute MI, and are now widely used both clinically and in the assessment of new reperfusion strategies.


Dr. Gibson is on the editorial board of Circulation. Dr. Gibson is Editor-in-Chief of Clinical Trial Results where he created the first weekly TV show for Cardiologists "This Week in Cardiology". Over 80,000 slidesets per month are downloaded from the site. Gibson also created TIMI.org, the website of the TIMI Study Group.


Dr. Gibson edited a textbook entitled “Management Strategies in Interventional Cardiology” which is optimized for hand held devices. Dr. Gibson authors the chapter on Primary Angioplasty in Randomized Trials in Cardiovascular Disease published as a companion to Braunwald's Heart Disease. He co-authors the chapter “Recognition and Management of Patients with Stable Angina Pectoris in Braunwald and Goldman’s Primary Cardiology and co-authors the chapter on Quantitative Coronary Arteriography in Topol’s textbook of Interventional Cardiology. He is lead author of the section on myocardial perfusion imaging in a new imaging textbook which is a companion to Braunwald’s Heart Disease.


Dr. Gibson lectures internationally on the topics of acute MI, acute coronary syndromes, atherosclerosis, interventional cardiology and angiogenesis.

In 2007, Gibson was selected by Who's Who as the Clinical Researcher of the Year.

Disclosures:

Present Research/Grant Funding

NewCardio, Inc.; Schering Plough Corporation; Sanofi-Aventis; Baxter; FoldRx; Genentech, Inc.; Astra Zeneca; HeartScape Technologies; Fold Rx; Abbott; Cardica, Inc.; Johnson & Johnson Corporation; FibroGen, Inc.


Speakers Bureau

Schering Plough Corporation; Eli Lilly and Company; Daiichi Sankyo Company, Inc;


Consultant

The Medicines Company; Bayer Corporation; Archemix Corporation; Heartscape Technologies, Inc.; Angel Medical Systems; Schering Plough Corporation; Portola Corporation; John & Johnson Corporation; ICON Medical Imaging; Jim Moran Heart and Vascular Research Institute


Stock Ownership

My wife owns stock in HealthMarx Inc.


Royalties as a Contributor

UpToDate in Cardiovascular Medicine


Past Research/Grant Funding/Past Speakers Bureau/Past Consulting

ActivBiotics, Inc.; Acusphere, Inc.; Astra; Sanofi-Aventis Corporation; Bard Corporation; Boston Scientific Corporation; Bristol Meyers Squibb Company; British Biotech, plc.; Ciba Geigy Corporation; Corgentech, Inc.; COR Therapeutics; DVI Guidant Corporation; GlaxoSmithKline; Genentech, Inc.; Merck & Co., Inc.; Millennium Pharmaceuticals; NIH; Pfizer; Percusurge, Inc.; Smith Kline Beecham; Sonus; St. Jude Medical; timi3 Systems, Inc.; Ascenta Therapeutics, Inc; CardioKinetix, Inc.; Eli Lilly and Company; KAI Pharmaceuticals; Nuvelo; INO Therapeutics, LLC; Point Biomedical Corporation; Portola Pharmaceuticals, Inc.; The Medicines Company; Ascenta Therapeutics; Atrium Medical Corporation; Biogen IDEC; PDL Pharmaceuticals; timi3 Systems; Momenta Pharmaceuticals; Novartis Corporation;